News | March 07, 2011

Occlutech Wins Swedish Court Ruling Against AGA-St. Jude Medical

March 4, 2011 - Occlutech GmbH received a favorable court ruling in Stockholm, Sweden in the ongoing patent litigation case with AGA Medical-St. Jude Medical.

In the ruling by Stockholm’s Tingsratt , the district court of Stockholm, the court does not see any basis for AGA-St Jude's claim that the Occlutech atrial septal defect (ASD) and patent foramen ovale (PFO) occluders violate any patent brought forward in the litigation. The Stockholm court decision is similar to the first instance ruling in the United Kingdom, which was confirmed by the appeal court in the United Kingdom, the last one received mid-2010. The U.K. ruling is final as the U.K. supreme court did not allow an appeal requested by AGA. The favorable Stockholm ruling is also similar to first instance as well as appeal court decisions in The Hague, in the Netherlands, the last one obtained in the end of 2010.

The rulings in Sweden and The Netherlands are subject to appeal by AGA-St. Jude Medical.

Throughout the litigation, Occlutech's owners and investors have funded work in maintaining and substantially strengthening Occlutech's own patent position. In 2011 and 2012, Occlutech expects to launch additional occluders for indications such as patent ductus arteriosus (PDA) and ventricular septal defect (VSD) in addition to second generation ASD and PFO occluders. Also, an innovative left atrial appendage (LAA) occluder, a new generation of stent grafts and cardiac valve intervention technologies are being developed.

For more information:

Related Content

Videos | Structural Heart Occluders | November 08, 2017
John Rhodes, M.D., co-director of the adult congenital heart program, Medical University of South Carolina, is the pr
Videos | Structural Heart Occluders | September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
University of Alabama at Birmingham, Amplatzer PFO Occluder, first implementation
News | Structural Heart Occluders | February 15, 2017
Doctors at the University of Alabama at Birmingham have implemented the first U.S. Food and Drug Administration (FDA)-...
Amplatzer PFO Occluder, St. Jude Medical, Baylor Heart and Vascular Services, Fort Worth, Texas, first patients
News | Structural Heart Occluders | February 01, 2017
Baylor Heart and Vascular Services at Fort Worth in November became the first program in Texas to implant the Amplatzer...
RESPECT trial, Amplatzer PFO Occluder, St. Jude Medical, TCT 2016
News | Structural Heart Occluders | November 02, 2016
St. Jude Medical Inc. announced the long-term data from RESPECT, a landmark trial, during a First Report session at the...
St. Jude Medical, Amplatzer PFO Occluder, FDA approval, U.S. launch
Technology | Structural Heart Occluders | November 02, 2016
St. Jude Medical Inc. announced this week the U.S. Food and Drug Administration (FDA) approval and launch of the...
PFO closure, patent foramen ovale, AAN recommendation, American Academy of Neurology, stroke patients
News | Structural Heart Occluders | August 08, 2016
Updated recommendations from the American Academy of Neurology (AAN) states that catheter-based closure should not be...
Videos | Structural Heart Occluders | June 16, 2016
This is an animation, supplied by Gore, demonstrated how the Cardioform Septal Occluder is implanted for the transcat
PFO occluder, amplatzer
Feature | Structural Heart Occluders | May 27, 2016 | Dave Fornell
May 27, 2016 — A U.S.
Videos | Structural Heart Occluders | November 05, 2012
Positive results from the RESPECT trial of transcatheter PFO vs.
Overlay Init